Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 19/20 | 1.00 |
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29634862 | 0.99 | DRD4 (0.98) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4009701 | 0.95 | DRD4 (0.90) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4003699 | 0.89 | DRD4 (0.80) | DRD4DRD2DRD3 | |
| SCHEMBL4003239 | 0.89 | DRD4 (0.80) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4011218 | 0.87 | DRD4 (0.77) | DRD4DRD2DRD3 | |
| SCHEMBL4002702 | 0.87 | DRD4 (0.77) | DRD4DRD2DRD3 | |
| SCHEMBL6214311 | 0.87 | DRD4 (0.76) | DRD4DRD2DRD3 | |
| SCHEMBL6246250 | 0.87 | DRD4 (0.76) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4002711 | 0.85 | DRD4 (1.00) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL4003541 | 0.85 | DRD4 (0.76) | DRD4DRD2DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072042-A1 | METHODS FOR IMPROVED IMMUNOTHERAPY | LEVITE MIA (IL) | 2022-03-10 | — | — | US | claimed |
| US-20180064707-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING POSTTRAUMATIC STRESS DISORDER | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2018-03-08 | — | — | US | claimed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | claimed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | claimed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12455279-B2 | Personalized immunotherapy for rejuvenating activating and strengthening exhausted and dysfunctional T cells, reducing PD-1, and improving immune function | LEVITE MIA (IL) | 2025-10-28 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-12331051-B2 | LSD derivatives, synthesis and method for treatment of diseases and disorders | BETTERLIFE PHARMA INC. (CA) | 2025-06-17 | — | — | US | disclosed |
| US-12201628-B2 | Neuronal modulation | TECHNION RESEARCH &DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-01-21 | — | — | US | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | DRD4 1334/4885DRD2 1439/4885DRD3 1741/4885 |
| US-12331051-B2 | LSD derivatives, synthesis and method for treatment of diseases and disorders | HTR4, SLC6A4, HRH4 | DRD4 71/4885DRD2 101/4885DRD3 123/4885 |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | DRD4 544/4885DRD2 576/4885DRD3 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.